Sinusitis: a possible link with adalimumab
Sinusitis: a possible link with adalimumab
复制标题
鼻窦炎：可能与阿达木单抗有关
DOI：
10.1007/s10067-008-0948-3
复制
发表时间：
2008
影响因子：
3.4
通讯作者：
M. Phelan
中科院分区：
文献类型：
--
作者：
M. Haroon;U. Bond;M. Phelan
抗肿瘤坏死因子药物的经验相对较短；随着时间的推移，我们正在更多地了解不同不良事件的发生频率，因为最初的试验要么太小，要么太短。我们报告了4例慢性炎症性关节炎患者[类风湿性关节炎(n= )3例和银屑病关节炎(n= 1)]。他们的炎症性关节炎仍然对每周增加剂量高达20 mg的甲氨蝶呤无效，需要在治疗肿瘤坏死因子拮抗剂方面取得进展。然而，在这些患者开始服用阿达利单抗后的几周内，他们出现了新诊断的复发性鼻窦炎。所有患者均由耳鼻咽喉科医生进行评估，并经临床确诊。鼻窦炎仍然对标准药物无效；然而，在停用阿达利玛单抗后，它消失了。尽管FDA和爱尔兰药学健康协会描述使用阿达利单抗会略微增加非严重感染的风险，而且大多数患者在感染缓解后继续服用Humira(阿达利单抗)，然而，我们最近的观察引起了人们对可能更高发病率的担忧。
The experience with anti-TNF agents is relatively short; and with time, we are learning more about the frequency of occurrence of different adverse events as the original trials were either too small or too brief. We report a case series of four patients who suffered from chronic inflammatory arthritis [rheumatoid arthritis (n= 3) and psoriatic arthritis (n= 1)]. Their inflammatory arthritis remained refractory to increasing doses of methotrexate up to 20 mg weekly and required an advance in treatment to TNF antagonists. However, within a few weeks of commencing these patients on adalimumab, they developed newly diagnosed recurring sinusitis. All these patients were assessed by otorhinolaryngologists, and had clinically confirmed diagnosis. The sinusitis remained refractory to standard medications; however, it resolved after the discontinuation of adalimumab. Although FDA and Irish Pharmaceutical Health Association describe that adalimumab use increases the risk of non-serious infections marginally and most of the patients continued on Humira (adalimumab) after the infection was resolved, however, our recent observation raises the concern of probable higher incidence.